Fundraising Fox
Valérie Calenda
InvestorManaging Partner at Mérieux Equity Partners · Principal at MIG Capital AG
Lyon, Auvergne-Rhône-Alpes, France
Find your path to Valérie
Sign up to see every warm intro you have to Valérie
- Paths you didn't know you had: your email and LinkedIn already hold routes to Valérie. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
About
Valérie Calenda is a Managing Partner at Mérieux Equity Partners, which she joined as Partner in January 2010, focusing on venture deal flow and investments and supporting more than ten companies in Europe and North America. She began her career as a research scientist in hematology and virology at Inserm before joining Transgene S.A., where she managed programs in HIV, cardiovascular disease, and oncology, advanced product candidates to clinical stage, and contributed to license agreements including a 2007 agreement with Hoffmann-La Roche on the HPV cancer vaccine candidate TG4001. She holds a PhD in pharmacology, a degree in hematology, and a B.Sc. in biochemistry-immunology from the University of Marseille, and serves on the boards of companies including Amyl Therapeutics, Keranova, AcuSurgical, Deepull, Biophta, and Prodigest.
Contact· self-published, not guessed
Colleagues at Mérieux Equity Partners
Frequently asked questions
- Who is Valérie Calenda?
- Valérie Calenda is a Managing Partner at Mérieux Equity Partners, which she joined as Partner in January 2010, focusing on venture deal flow and investments and supporting more than ten companies in Europe and North America. She began her career as a research scientist in hematology and virology at Inserm before joining Transgene S.A., where she managed programs in HIV, cardiovascular disease, and oncology, advanced product candidates to clinical stage, and contributed to license agreements including a 2007 agreement with Hoffmann-La Roche on the HPV cancer vaccine candidate TG4001. She holds a PhD in pharmacology, a degree in hematology, and a B.Sc. in biochemistry-immunology from the University of Marseille, and serves on the boards of companies including Amyl Therapeutics, Keranova, AcuSurgical, Deepull, Biophta, and Prodigest.
- Where does Valérie Calenda work?
- Valérie Calenda is Managing Partner at Mérieux Equity Partners and Principal at MIG Capital AG.
About this profile. Compiled from public sources — Mérieux Equity Partners's own website and public professional profiles — and summarised by Fundraising Fox; every fact is kept with where it came from. Spotted an error, or would rather not be listed? Email privacy@fundraisingfox.com · How we build profiles · Your rights